DK1999152T3 - Bindende element til gm-csf-receptor - Google Patents

Bindende element til gm-csf-receptor

Info

Publication number
DK1999152T3
DK1999152T3 DK07712963.3T DK07712963T DK1999152T3 DK 1999152 T3 DK1999152 T3 DK 1999152T3 DK 07712963 T DK07712963 T DK 07712963T DK 1999152 T3 DK1999152 T3 DK 1999152T3
Authority
DK
Denmark
Prior art keywords
binding element
csf receptor
csf
receptor
binding
Prior art date
Application number
DK07712963.3T
Other languages
English (en)
Inventor
Andrew Donald Nash
Louis Jerry Fabri
Emma Suzanne Cohen
Ralph Raymond Minter
Paula Rosamund Harrison
Matthew Alexander Sleeman
Original Assignee
Medimmune Ltd
Zenyth Operations Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd, Zenyth Operations Pty Ltd filed Critical Medimmune Ltd
Application granted granted Critical
Publication of DK1999152T3 publication Critical patent/DK1999152T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
DK07712963.3T 2006-03-27 2007-03-27 Bindende element til gm-csf-receptor DK1999152T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78656906P 2006-03-27 2006-03-27
PCT/GB2007/001108 WO2007110631A1 (en) 2006-03-27 2007-03-27 Binding member for gm-csf receptor

Publications (1)

Publication Number Publication Date
DK1999152T3 true DK1999152T3 (da) 2013-01-14

Family

ID=38293698

Family Applications (3)

Application Number Title Priority Date Filing Date
DK07712963.3T DK1999152T3 (da) 2006-03-27 2007-03-27 Bindende element til gm-csf-receptor
DK11167923.9T DK2423230T3 (da) 2006-03-27 2007-03-27 Bindingselement til GM-CSF-receptor
DK11167912.2T DK2423229T3 (da) 2006-03-27 2007-03-27 Bindingselement til GM-CSF-receptor

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK11167923.9T DK2423230T3 (da) 2006-03-27 2007-03-27 Bindingselement til GM-CSF-receptor
DK11167912.2T DK2423229T3 (da) 2006-03-27 2007-03-27 Bindingselement til GM-CSF-receptor

Country Status (16)

Country Link
US (8) US8263075B2 (da)
EP (3) EP1999152B1 (da)
JP (2) JP5335662B2 (da)
KR (2) KR101481844B1 (da)
CN (3) CN103641915B (da)
BR (1) BRPI0709259B1 (da)
CA (1) CA2647449C (da)
DK (3) DK1999152T3 (da)
ES (3) ES2424468T3 (da)
HK (2) HK1166988A1 (da)
MX (2) MX348827B (da)
PL (3) PL2423230T3 (da)
PT (3) PT2423229E (da)
RU (2) RU2495050C2 (da)
SI (3) SI2423230T1 (da)
WO (1) WO2007110631A1 (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2424468T3 (es) * 2006-03-27 2013-10-02 Medimmune Limited Miembro de unión para el receptor GM-CSF
NZ598345A (en) 2006-11-21 2013-09-27 Kalobios Pharmaceuticals Inc Methods of treating chronic inflammatory diseases using a gm-csf antagonist
US8075885B2 (en) 2008-04-07 2011-12-13 Kalobios Pharmaceuticals, Inc. Methods of treating heart failure using an anti-GM-CSF antibody
JP5674677B2 (ja) 2008-12-22 2015-02-25 ザ ユニバーシティー オブ メルボルンＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ ｏｆ Ｍｅｌｂｏｕｒｎｅ 疼痛治療
AU2015224416B2 (en) * 2008-12-22 2017-04-20 The University Of Melbourne Osteoarthritis treatment
KR101898982B1 (ko) * 2008-12-22 2018-09-14 더 유니버시티 오브 멜버른 골관절염 치료
CN102459340A (zh) * 2009-04-23 2012-05-16 特罗科隆科学有限公司 粒性白血细胞-巨噬细胞菌落-刺激因子(gm-csf)中和抗体
CA2760755A1 (en) * 2009-05-05 2010-11-11 Morphosys Ag Treatment for multiple sclerosis
US20120165220A1 (en) * 2009-09-03 2012-06-28 Colgan Sean P Uses of CD116 Expression Level
US20140335081A1 (en) * 2011-10-10 2014-11-13 Medlmmune Limited Treatment For Rheumatoid Arthritis
EP2780363B1 (en) * 2011-11-17 2019-07-03 Glia SP Z.O.O. Compositions and methods for treating glioma
EP2602264A1 (en) 2011-12-05 2013-06-12 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka mbH GDF-5 mutant for inducing cartilage formation
WO2013090989A1 (en) 2011-12-22 2013-06-27 Csl Limited Method of treating inflammatory bowel disease
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
EP2914289B1 (en) 2012-10-31 2019-05-22 Takeda GmbH Lyophilized formulation comprising gm-csf neutralizing compound
JP6475166B2 (ja) 2012-12-14 2019-02-27 バイオエヌテク アールエヌエー ファーマシュティカルズ ジーエムビーエイチ 新規ｍｈｃ非依存性腫瘍関連抗原
CN103193882B (zh) * 2013-03-29 2014-11-05 浙江大学 胚胎干细胞特异性标志物GM-CSFRα及其应用
MX2016002177A (es) 2013-08-30 2016-06-28 Takeda Gmbh Anticuerpos neutralizantes de gm-csf para usarse en el tratamiento de artritis reumatoide o como analgesicos.
BR112016025126B1 (pt) 2014-05-07 2024-02-15 Takeda Pharmaceutical Company Limited Composição aquosa compreendendo anticorpo neutralizante de gmcsf, e uso da mesma
CN106456761A (zh) * 2014-05-19 2017-02-22 免疫医疗有限公司 对类风湿关节炎的治疗
GB201503139D0 (en) * 2015-02-25 2015-04-08 Univ Leicester Diagnostic and therapeutic target
GB201519331D0 (en) * 2015-11-02 2015-12-16 Glaxosmithkline Ip Dev Ltd Treatment paradigm
MA45112A (fr) 2016-05-24 2019-04-10 Medimmune Ltd Auto-anticorps anti-pad4 comme marqueurs biologiques de réponse clinique pour le traitement de l'arthrite rhumatoïde
WO2018158332A1 (en) * 2017-03-01 2018-09-07 Medimmune Limited Formulations of monoclonal antibodies
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
EP3623382A1 (en) 2018-09-14 2020-03-18 Universität Zürich Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
US11078264B2 (en) 2018-10-17 2021-08-03 University Of Connecticut Inhibiting granulocyte macrophage-colony stimulating factor (GM-CSF) prevents preterm birth
WO2020096664A1 (en) 2018-11-09 2020-05-14 Kiniksa Pharmaceuticals, Ltd. Treatment for giant cell arteritis
WO2020097321A1 (en) 2018-11-09 2020-05-14 Kiniksa Pharmaceuticals, Ltd. Treatment for giant cell arteritis
EP3902835A4 (en) * 2018-11-27 2022-08-17 Staidson (Beijing) Biopharmaceuticals Co., Ltd. ANTIBODIES SPECIFICALLY RECOGNIZING GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR ALPHA AND THEIR USES
EP3976080A1 (en) 2019-06-03 2022-04-06 Kiniksa Pharmaceuticals, Ltd. Treatment of cancers with gm-csf antagonists
US20230030680A1 (en) * 2020-01-07 2023-02-02 St. Jude Children's Research Hospital, Inc Chimeric gmcsf-il18 receptor
US20210284744A1 (en) * 2020-03-15 2021-09-16 Kiniksa Pharmaceuticals, Ltd. Treatment of cytokine release syndrome with gm-csf antagonists
WO2021204649A1 (en) 2020-04-06 2021-10-14 Glaxosmithkline Intellectual Property Development Limited Gm-csf antagonists for use in the treatment of severe pulmonary covid-19, cytokine release syndrome and/or acute respiratory distress syndrome
CN111690063A (zh) * 2020-05-25 2020-09-22 北京大学 一种抗gm-csf纳米抗体及其制备方法和应用
WO2022093855A1 (en) 2020-10-26 2022-05-05 Kiniksa Pharmaceuticals, Ltd. Treatment of cancers with gm-csf antagonists
US20220281914A1 (en) 2020-12-18 2022-09-08 Kiniksa Pharmaceuticals, Ltd. Protein compositions and methods for producing and using the same
WO2023138499A1 (zh) * 2022-01-20 2023-07-27 舒泰神（北京）生物制药股份有限公司 一种特异性地识别粒细胞-巨噬细胞集落刺激因子受体的抗体制剂及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5629283A (en) * 1989-08-11 1997-05-13 Amrad Corporation Limited Granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof
AU637133B2 (en) * 1989-08-11 1993-05-20 Amrad Operations Pty. Limited Improvements in granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5747032A (en) 1990-08-10 1998-05-05 Amrad Corporation Limited Monoclonal antibody to human granulocyte macrophage colony stimulating factor
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
WO1994011404A1 (en) 1992-11-19 1994-05-26 Dana-Farber Cancer Institute Antibodies for gm-csf receptor and uses thereof
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AUPN780096A0 (en) * 1996-01-30 1996-02-22 Medvet Science Pty. Ltd. Cytokine antagonists and agonists
DK1137941T4 (da) 1998-12-10 2014-01-06 Brystol Myers Squibb Company Protein-scaffolds til antistof-mimetika og andre bindingsproteiner
WO2001066754A1 (en) 2000-03-03 2001-09-13 Cambridge Antibody Technology Limited Human antibodies against eotaxin and their use
US7108852B2 (en) * 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
KR100453877B1 (ko) * 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
AU2003277087B2 (en) * 2002-06-14 2008-07-31 Immunomedics, Inc. Humanized monoclonal antiboby hPAM4
ATE471946T1 (de) * 2002-12-17 2010-07-15 Merck Patent Gmbh Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
US20040146486A1 (en) * 2003-01-24 2004-07-29 Juan Sun Hybrid vector system for use as a vaccine
ES2424468T3 (es) * 2006-03-27 2013-10-02 Medimmune Limited Miembro de unión para el receptor GM-CSF
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Also Published As

Publication number Publication date
RU2012157042A (ru) 2014-07-10
PT2423230E (pt) 2013-08-26
ES2424467T3 (es) 2013-10-02
KR20080113262A (ko) 2008-12-29
CN101443360A (zh) 2009-05-27
KR101451546B1 (ko) 2014-10-16
BRPI0709259B1 (pt) 2022-05-31
JP5335662B2 (ja) 2013-11-06
EP2423230A1 (en) 2012-02-29
CA2647449A1 (en) 2007-10-04
CN103641915B (zh) 2017-04-12
WO2007110631A1 (en) 2007-10-04
PL2423230T3 (pl) 2013-10-31
US20090130093A1 (en) 2009-05-21
ES2424468T3 (es) 2013-10-02
US20190040145A1 (en) 2019-02-07
EP2423229A1 (en) 2012-02-29
CN101443360B (zh) 2013-11-27
DK2423229T3 (da) 2013-08-05
SI1999152T1 (sl) 2013-02-28
US20210147559A1 (en) 2021-05-20
SI2423229T1 (sl) 2013-09-30
SI2423230T1 (sl) 2013-09-30
HK1166988A1 (en) 2012-11-16
RU2008137763A (ru) 2010-05-10
PT1999152E (pt) 2013-01-07
JP2009533020A (ja) 2009-09-17
PL1999152T3 (pl) 2013-05-31
EP1999152A1 (en) 2008-12-10
RU2495050C2 (ru) 2013-10-10
CN103641916A (zh) 2014-03-19
US9085628B2 (en) 2015-07-21
US20240124596A1 (en) 2024-04-18
EP2423230B1 (en) 2013-05-08
US20190309077A1 (en) 2019-10-10
US20150376285A1 (en) 2015-12-31
KR20130140186A (ko) 2013-12-23
PT2423229E (pt) 2013-08-22
HK1166989A1 (en) 2012-11-16
US8506960B2 (en) 2013-08-13
DK2423230T3 (da) 2013-08-05
JP2013121350A (ja) 2013-06-20
CA2647449C (en) 2017-05-16
MX348827B (es) 2017-06-30
MX2008012291A (es) 2009-01-12
PL2423229T3 (pl) 2013-09-30
JP5665894B2 (ja) 2015-02-04
CN103641915A (zh) 2014-03-19
ES2395839T3 (es) 2013-02-15
US8263075B2 (en) 2012-09-11
RU2639546C2 (ru) 2017-12-21
EP1999152B1 (en) 2012-09-19
US20120141464A1 (en) 2012-06-07
US20140079708A1 (en) 2014-03-20
AU2007231128A1 (en) 2007-10-04
KR101481844B1 (ko) 2015-01-13
EP2423229B1 (en) 2013-05-08
BRPI0709259A2 (pt) 2011-06-28

Similar Documents

Publication Publication Date Title
DK1999152T3 (da) Bindende element til gm-csf-receptor
DK2245064T3 (da) BINDINGSELEMENTER TIL INTERLEUKIN-4-RECEPTOR-ALFA (IL-4Ralfa)
DK2054711T3 (da) Fremgangsmåde til fremstilling af mikroarrays
BRPI0815075A2 (pt) Aglutinantes
DK1969279T3 (da) Koblingsdel til stikforbindelsesindretning
ATE509022T1 (de) Nikotin-acetylcholin-rezeptorsubtyp-selektive diazabicycloalkanamide
DK1852430T3 (da) Fremgangsmåde til fremstilling af proanthocyanidinoligomer
DK2044002T3 (da) Fremgangsmåde til fremstilling af 3-substituerede 2-amino-5-halobenzamider
DK2538222T3 (da) Biokemiske markører til cvd-risikovurdering
ATE525624T1 (de) Betätigungselement
DK1888960T3 (da) Forankringselement til rörkoblinger
DK2073636T3 (da) Fremgangsmåde til fremstilling af oxymorphon
CR10705A (es) Anticuerpos para linfotoxina-alfa
DK2101733T3 (da) Pulverformulering til valganciclovir
DK1745860T3 (da) Forskydelig støttestruktur til tragt
ATE459770T1 (de) Montageelement
DK2069093T3 (da) Nedholder til pladesakse
DK2203410T3 (da) Fremgangsmåde til fremstilling af 4-aminobut-2-enolider
DK1973410T3 (da) Fremgangsmåde til mængdedeling af dej
PL386231A1 (pl) Element mocujący
DE602007008589D1 (de) Pyridooxazepin-progesteronrezeptor-modulatoren
ES1065168Y (es) Soporte para biberon
FI20070466A0 (fi) Sidontalaite
ITVI20060052A1 (it) Dispositivo di legatura rapida
ITCN20060002A1 (it) Imbiellaggio martino